Recombinant Human Anti-E protein Antibody (E76) (CAT#: FAMAB-0117CQ)

Figure 1 Anti-DENV MAbs are therapeutic following a virus-only or antibody-enhanced lethal infection.

A. Ribbon diagram of the DENV2 E protein homodimer (PDB ID code 1OAN). EDI is red, EDII is yellow and EDIII is blue. The epitopes targeted by MAbs include the fusion loop (green), dimer interface (white), C-C′ loop (orange) and A strand (magenta). B. AG129 mice were administered a lethal dose of DENV2 D2S10 and 24 hours later were treated with 20 µg of modified MAbs (n = 5 per group from 2 independent experiments). C. AG129 mice were administered an enhancing dose of polyvalent DENV1-immune mouse serum, infected with DENV2 D2S10, and 24 hours later treated with 20 µg of modified MAbs. (n = 3–19 per group from at least 2 independent experiments for each modified MAb). A Kaplan-Meier survival curve is shown (B–C), and log-rank analysis was used for statistical comparison.

Williams, K. L., Sukupolvi-Petty, S., Beltramello, M., Johnson, S., Sallusto, F., Lanzavecchia, A., ... & Harris, E. (2013). Therapeutic efficacy of antibodies lacking FcγR against lethal dengue virus infection is due to neutralizing potency and blocking of enhancing antibodies. PLoS pathogens, 9(2), e1003157.

Figure 2 In vitro suppression-of-enhancement assay predicts therapeutic efficacy of MAbs in vivo with enhancing polyvalent DENV-immune serum from mice.

A. The peak enhancing titer (PENT = 1∶180) for DENV1-immune mouse serum was determined in K562 cells. B. DENV1-immune mouse serum was diluted 1∶180 (PENT) and incubated with modified MAbs at six 2-fold dilutions beginning at 2,000 ng/ml. Relative infection was calculated by dividing the percent infection in the presence of modified MAbs by the percent infection measured with mouse DENV1-immune serum alone. The data displayed are the average of duplicate values and are representative of four independent experiments. A † indicates modified MAbs that are statistically therapeutic in vivo following mouse DENV1-enhanced, lethal DENV2 infection. C. The average infection across four experiments at 1,000 ng/ml of modified MAb (mean +/− SEM shown for each MAb). P<0.04 was obtained when comparing the average relative infection values for therapeutic to non-therapeutic MAbs using a Wilcoxon rank-sum analysis. The solid line indicates relative infection of 0.5 (50% infection).

Williams, K. L., Sukupolvi-Petty, S., Beltramello, M., Johnson, S., Sallusto, F., Lanzavecchia, A., ... & Harris, E. (2013). Therapeutic efficacy of antibodies lacking FcγR against lethal dengue virus infection is due to neutralizing potency and blocking of enhancing antibodies. PLoS pathogens, 9(2), e1003157.

Figure 3 In vitro suppression-of-enhancement assay correlates with therapeutic efficacy of MAbs in vivo with enhancing polyvalent DENV-immune serum from humans.

A. The PENT (1∶540) for DENV4-immune human serum was determined in K562 cells. B. DENV4-immune human serum diluted 1∶540 was incubated with modified MAbs at 1,000 ng/ml. Relative infection was calculated. The data displayed are combined from five independent experiments, and the mean +/− SEM is displayed for each MAb. A sign rank test was used to determine whether relative infection with each modified MAb was significantly lower than relative infection of 0.5 (50% infection), * P<0.05, ** P<0.08. C. AG129 mice (n = 3 per experimental group and n = 6 for non-treated control group) were administered an enhancing dose of DENV4-immune human serum, infected with DENV2 D2S10, and 24 hours later treated with 20 µg of modified MAbs. A Kaplan-Meier survival curve is shown, and log-rank analysis was used for statistical comparison.

Williams, K. L., Sukupolvi-Petty, S., Beltramello, M., Johnson, S., Sallusto, F., Lanzavecchia, A., ... & Harris, E. (2013). Therapeutic efficacy of antibodies lacking FcγR against lethal dengue virus infection is due to neutralizing potency and blocking of enhancing antibodies. PLoS pathogens, 9(2), e1003157.